

Claims

- 1 A method of treatment of psoriasis which comprises administering to a patient in need thereof by the oral route a pharmaceutical composition comprising rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, together with a
5 pharmaceutically acceptable carrier, wherein the method comprises administering 2 to 8 mg rosiglitazone per day.
2. A method according to claim 1 wherein the method comprises administering 2mg rosiglitazone per day.
3. A method according to claim 1 wherein the method comprises administering 4mg
10 rosiglitazone per day.
4. A method according to claim 1 wherein the method comprises administering 8mg rosiglitazone per day.
5. A method according to any one of claims 1 to 3 wherein the method comprises administering the rosiglitazone once per day in a single dose or sequentially in two or
15 more divided doses.
6. A method according to any one of claims 1 to 5 wherein the patient is suffering from moderate to very severe psoriasis.
7. A method according to any one of claims 1 to 6 wherein the treatment is continued for 12 weeks or more.
- 20 8. A method according to claim 7 wherein the treatment is continued for 18 weeks or more.
9. A method according to any one of claims 1 to 8 wherein the rosiglitazone is employed as its maleate salt.
10. A method of treatment of psoriasis in a patient which comprises
25 (a) diagnosing psoriasis in a patient
(b) administering to said patient by the oral route a pharmaceutical composition comprising rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, in an amount of 2 to 8 mg rosiglitazone per day.
- 30 11. A method according to claim 10 which is a method of treatment of moderate to very severe psoriasis and step (a) comprises diagnosing moderate to very severe psoriasis in the patient.
12. A method according to claim 10 or claim 11 wherein in step (a) the patient is diagnosed with severe or very severe psoriasis.
- 35 13. A method according to any one of claims 10 to 12 wherein in step (b) the rosiglitazone is administered once per day in a single dose or sequentially in two or more divided doses.

14. A method according to any one of claims 10 to 13 wherein in step (b) rosiglitazone is administered to a patient for a continuous period of 12 weeks or more.
15. A method according to claim 14 wherein in step (b) rosiglitazone is administered to a patient for a continuous period of 18 weeks or more.
- 5 16. A method according to any one of claims 1 to 15 which also comprises administering another medicament effective in the treatment of psoriasis with fast onset of activity.
17. A method according to claim 16 wherein the another medicament effective in the treatment of psoriasis with fast onset of activity is administered until the rosiglitazone becomes effective.
- 10 18. A method according to claim 16 or claim 17 wherein the another medicament is hydrocortisone.
19. A method according to any one of claims 1 to 18 wherein the patient also suffers from NIDDM.
20. A method according to any one of claims 1 to 18 wherein the patient does not also suffers from NIDDM.
- 15 21. A kit for the treatment of psoriasis comprising:
- (a) A pharmaceutical composition comprising 2 to 8 mg rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier in a single dose or in two or more divided doses per day of treatment; and
- 20 (b) instructions directing the oral administration by a patient suffering from psoriasis of 2 to 8 mg rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier per day of treatment.
- 25 22. A kit according to claim 21 wherein the instructions direct the the oral administration by a patient suffering from psoriasis of 2 to 8 mg rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier once per day of treatment in a single dose or sequentially in two or more divided doses.
- 30 23. A kit according to claim 21 or claim 22 wherein the rosiglitazone is employed as its maleate salt.
24. A kit according to any one of claims 21 to 23 which also contains another medicament effective in the treatment of psoriasis with fast onset of activity.
25. A kit according to claim 24 including instructions to the patient to administer the another medicament effective in the treatment of psoriasis with fast onset of activity is administered until the rosiglitazone becomes effective.
- 35

26. A kit according to claims 24 or claim 25 wherein the another medicament is hydrocortisone.
27. A kit according to any one of claim 21 to 26 wherein the patient also suffers from NIDDM.
- 5 28. A kit according to any one of claim 21 to 26 wherein the patient does not also suffer from NIDDM.
29. Use of rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the oral treatment of psoriasis wherein said rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, is used in a
10 pharmaceutical composition together with a pharmaceutically acceptable carrier, in an amount of 2 to 8 mg rosiglitazone per day of treatment.
30. Use according to claim 29 wherein the rosiglitazone is used in a composition containing 2 to 8 mg rosiglitazone in a single dose or sequentially in two or more divided doses.
- 15 31. Use according to claim 29 or claim 30 wherein the rosiglitazone is employed as its maleate salt.
32. Use of rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, in the oral treatment of psoriasis wherein said rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, is used in a pharmaceutical composition together
20 with a pharmaceutically acceptable carrier, in an amount of 2 to 8 mg rosiglitazone per day of treatment.
33. Use according to claim 32 wherein the rosiglitazone is used in a composition containing 2 to 8 mg rosiglitazone in a single dose or sequentially in two or more divided doses.
- 25 34. Use according to claim 32 or claim 33 wherein the rosiglitazone is employed as its maleate salt.
35. Use of rosiglitazone according to any one of claims 32 to 34 in combination with another medicament having fast onset of action in the treatment of psoriasis.
36. Use according to claim 35 wherein the other medicament is hydrocortisone.
- 30 37. Use according to any one of claims 29 to 36 wherein the method involves treatment of a patient also suffering from NIDDM.
38. Use according to any one of claims 29 to 36 wherein the method involves treatment of a patient not also suffering from NIDDM.
39. Rosiglitazone, or a pharmaceutically acceptable salt thereof, for use in the treatment
35 of psoriasis by the oral route in a pharmaceutical composition together with a carrier at a dosage of 2 to 8 mg rosiglitazone per day.

40. Rosiglitazone according to claim 39 wherein the composition contains 2 to 8 mg rosiglitazone in a single dose or sequentially in two or more divided doses.
41. Rosiglitazone according to claim 39 or claim 40 wherein the rosiglitazone is employed as its maleate salt.
- 5 42. Rosiglitazone according to any one of claims 39 to 41 in combination with another medicament having fast onset of action in the treatment of psoriasis.
43. Rosiglitazone according to claim 42 wherein the other medicament is hydrocortisone.
44. Rosiglitazone according to any one of claims 39 to 32 wherein the treatment involves treatment of a patient also suffering from NIDDM.
- 10 45. Rosiglitazone according to any one of claims 39 to 44 wherein the treatment involves treatment of a patient not also suffering from NIDDM.